Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.

Background: Venous thromboembolism (VTE) is a concern for patients with newly diagnosed multiple myeloma.

Objectives: We aimed to evaluate VTE incidence, risk factors, and risk score.

Patients/methods: We performed a substudy of the "Intergroupe Francophone du Myelome 2009" randomized controlled trial.

Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study.

Background: Multiple myeloma (MM) is associated with a high risk of thrombosis, particularly during the first months of treatment including immunomodulatory drugs (IMiDs). There is no consensus on prevention of thromboembolic risk in patients with de novo MM, and identification of patients requiring anticoagulant thromboprophylaxis remains challenging. Evaluating coagulability by an in vitro thrombin generation (TG) test might be a way of identifying such patients.

Multimodal Outcome at 7 Years of Age after Neonatal Arterial Ischemic Stroke.

Objectives: To evaluate the epileptic, academic, and developmental status at age 7 years in a large population of term-born children who sustained neonatal arterial ischemic stroke (NAIS), and to assess the co-occurrence of these outcomes.

Study Design: A cohort study including 100 term newborns with NAIS was designed. Two infants died during the neonatal period, 13 families were lost to follow-up, and 5 families declined to participate in this evaluation.